COVID-19 has unleashed a logistical conundrum for pharma lab leaders: How do you keep momentum in therapeutics development, when, like all workplaces, most labs have had to either restrict use or close altogether? The answer lies, at least in part, i ...
Novartis' Lung Cancer Drug Gets European Approval Article taken from http://www.dddmag.com/news/2015/05/novartis-lung-cancer-drug-gets-european-approval Novartis announced that the European Commission has approved Zykadia (ceritinib) to treat adult ...
While personalized medicine has been a goal for some time, there have been several obstacles. Although there has been an explosion in genomic data, the corresponding clinical utility for this data has been slow to be validated. Data from tissue image ...
Nanoparticle drugs—tiny containers packed with medicine and with the potential to be shipped straight to tumors—were thought to be a possible silver bullet against cancer. However new cancer drugs based on nanoparticles have not improved overall sur ...
At the Virginia Tech Carilion Research Institute, three scientists are planning to create a virus capable of destroying brain cancer. It sounds like the stuff of science fiction, but it isn’t hypothetical – the researchers were recently awarded a g ...
Federal health experts have unanimously endorsed a Novartis drug which is expected to become the first lower-cost copy of a biotech drug to reach the U.S. market. A panel of Food and Drug Administration experts ruled that the company's version of N ...
Researchers Find Alternate Drug Therapy Lowers Antibodies Findings of a three-year clinical trial led by University of Cincinnati (UC) transplant researchers suggest that a novel pre-operative drug therapy reduces antibodies in kidney patients with ...
Researchers Map Paths to Cancer Drug Resistance A team of researchers led by Duke Cancer Institute has identified key events that prompt certain cancer cells to develop resistance to otherwise lethal therapies By mapping the specific steps that cell ...
An experimental cancer drug may block an important driver for the survival, growth and spread of cancer cells. The first clinical trial of an experimental drug, called pictilisib, found the safety profile to be manageable in cancer patients at dose ...
Results of a small Johns Hopkins Children’s Center study show that hospitalized children given high-dose IV infusions of the antibiotic vancomycin to treat drug-resistant bacterial infections face an increased risk for kidney damage — an often rever ...
